Skip to main content

Table 1 Subscales of health-related quality of life by patients’ characteristics at baseline and responses to TKI therapy within 1 year

From: Achieving optimal response at 12 months is associated with a better health-related quality of life in patients with chronic myeloid leukemia: a prospective, longitudinal, single center study

Variable No (%) PF RP BP GH PCS VT SF RE MH MCS
Median P Median P Median P Median P Median P median P Median P Median P Median P Meidan P
Gender    0.61   0.75   0.58   0.44   0.84   0.36   0.024   0.18   0.91   0.087
 Male 35 (59.3) 56.46   48.15   50.24   52.62   49.67   58.61   52.53   54.81   58.94   54.13  
 Female 24 (40.7) 56.46   51.88   50.25   55.84   51.14   61.00   59.55   54.81   58.06   58.76  
Age    0.056   0.66   0.55   0.78   0.62   0.96   0.73   0.14   0.42   0.85
 < 40 years 33 (55.9) 56.46   48.15   54.15   56.58   50.29   58.61   59.55   54.81   57.18   56.54  
 ≥ 40 years 26 (44.1) 53.94   51.88   46.34   53.86   50.31   58.61   52.53   49.67   58.94   55.40  
Education    0.36   0.85   0.40   0.54   0.64   0.19   0.66   0.14   0.026   0.030
 ≥ Bachelor degree 24 (40.7) 56.46   48.15   54.15   55.35   51.94   62.20   52.53   54.81   60.70   52.60  
 < Bachelor degree 35 (59.3) 56.46   55.60   46.34   55.10   49.67   58.61   59.55   54.81   55.42   59.58  
TKI used    0.52   0.71   0.98   0.042   0.38   0.87   0.49   0.49   0.23   0.40
 Imatinib 31 (52.5) 56.46   55.60   54.15   52.62   49.01   58.61   52.53   54.81   58.94   57.29  
 Nilotinib 28 (47.5) 57.73   48.15   50.24   58.32   52.21   59.81   59.55   54.81   57.18   52.93  
Sokal risk    0.63   0.31   0.67   0.48   0.17   0.29   0.32   0.84   0.47   0.99
 Low 28 (47.5) 56.46   48.15   48.29   54.60   48.35   58.61   52.53   54.81   58.94   56.07  
 Intermediate / High 18 (30.5) /13 (22.0) 56.46   55.60   54.15   55.10   52.52   58.61   59.55   54.81   57.18   56.54  
Response at 3 months    0.35   0.26   0.30   0.36   0.20   0.71   0.94   0.41   0.83   0.80
 Optimal 44 (74.6) 56.46   48.15   48.29   52.62   49.20   58.61   56.04   54.81   58.06   56.60  
 Warning / Failure 9 (15.3) /6 (10.1) 58.99   55.60   54.15   59.06   52.28   58.61   52.53   54.81   58.94   55.22  
Response at 6 months    0.52   0.45   0.77   1.0   0.35   0.44   0.52   0.89   0.74   0.92
 Optimal 43 (72.9) 56.46   48.15   54.15   55.10   49.38   58.61   52.53   54.81   58.94   55.46  
 Warning / Failure 9 (15.3) /7 (11.9) 57.73   55.60   48.29   55.35   51.29   59.81   56.04   54.81   56.30   57.09  
Response at 12 months    0.65   0.85   0.49   0.92   0.29   0.43   0.91   0.37   0.64   0.40
 Optimal 28 (48.3) 56.46   48.15   48.29   53.86   48.74   59.81   56.04   54.81   58.06   57.11  
 Warning / Failure 16 (27.6) / 14 (24.1) 56.46   55.60   54.15   56.58   52.12   58.61   52.53   54.81   58.94   55.22  
  1. P value in bold and italics are significant with P < 0.05